Ignite Creation Date:
2025-12-25 @ 5:08 AM
Ignite Modification Date:
2025-12-26 @ 4:12 AM
Study NCT ID:
NCT04921527
Status:
RECRUITING
Last Update Posted:
2024-10-18
First Post:
2021-06-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Sponsor:
Chipscreen Biosciences, Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-20
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-07-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-06-03
First Submit QC Date:
None
Study First Post Date:
2021-06-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-17
Last Update Post Date:
2024-10-18
Last Update Post Date Type:
ACTUAL